Autologous Chondrocyte Transplantation/Implantation Versus Existing treatments: a randomised controlled trial

Keele University (UK)0 sites400 target enrollmentStarted: May 18, 2001Last updated: October 17, 2016

Trial Snapshot

No summary available.

•Current inclusion criteria as of 09/11/2012:
•1. Symptomatic chondral defect(s) on the medical or lateral femoral condyle, trochlea or patella suitable for either ACT or one of the existing conventional treatments (debridement, abrasion, drilling, microfracture, mosaicplasty)
•2. Surgical treatment for the same defect carried out at least 12 months previously, that has not relieved symptoms
•3. Not more than two defects, not kissing and total area not greater than 12cm2
•4. Likely to comply with appropriate physiotherapy
•Previous inclusion criteria until 09/11/2012:
•1. Symptomatic chondral defect(s) on the medical or lateral femoral condyle or trochlea suitable for either ACT or one of the existing conventional treatments (debridement, abrasion, drilling, microfracture, mosaicplasty)
•2. Surgical treatment for the same defect carried out at least 12 months previously, that has not relieved symptoms
•3. Not more than two defects, not kissing and total area not greater than 12cm2
•4. Likely to comply with appropriate physiotherapy

•1. Concurrent meniscectomy/osteotomy or untreated malalignment of patella
•2. Generalised osteoarthritis, inflammatory condition or history of mesenchymal tumors
•3. Patient in different clinical trial involving the knee, currently or in last 6 months

Sponsor

Keele University (UK)